Last reviewed · How we verify
ASTX727 Fixed-Dose Combination
At a glance
| Generic name | ASTX727 Fixed-Dose Combination |
|---|---|
| Also known as | ASTX727 oral (combination of oral E7727 and oral decitabine) |
| Sponsor | Astex Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (PHASE1)
- Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) (PHASE1, PHASE2)
- A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) (PHASE1)
- A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) (PHASE2)
- Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (PHASE1)
- A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS) (PHASE2)
- Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML (PHASE3)
- Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |